SBI Securities’s BioAtla BCAB Stock Holding History

SBI Securities’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.1K	Buy	267 +45	+20%	+$191	﹤0.01%	2771
2026 Q1	$1.79K	Buy	222 +46	+26%	+$538	﹤0.01%	2459
2025 Q4	$4.99K	Buy	176 +27	+18%	+$1.06K	﹤0.01%	2024
2025 Q3	$5.13K	Buy	149 +29	+24%	+$670	﹤0.01%	2035
2025 Q2	$2.38K	Buy	120 +38	+46%	+$771	﹤0.01%	2315
2025 Q1	$1.43K	Buy	82 +65	+382%	+$1.39K	﹤0.01%	2437
2024 Q4	$488	Buy	+17	New	+$1.43K	﹤0.01%	2896

SBI Securities's BCAB Position: Q2 2026 in Review

SBI Securities increased its BioAtla (BCAB) stake by 20% in Q2 2026, buying an estimated $191 and bringing the position to 267 shares worth $1.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2771.

SBI Securities first reported a position in BCAB in Q4 2024 and has held it in 7 quarters since. The position peaked at $5.13K in Q3 2025. 1 fund tracked by Wall St. Rank holds BCAB as of Q2 2026.

SBI Securities held 267 shares of BioAtla worth $1.1K as of Q2 2026.
SBI Securities bought 45 BioAtla shares in Q2 2026, an estimated $191.
BioAtla made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2771 holding.
SBI Securities first reported a position in BioAtla in Q4 2024 and has held it in 7 quarters since.
SBI Securities's BioAtla position peaked at $5.13K in Q3 2025.
1 fund tracked by Wall St. Rank held BioAtla as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.